Abstract
The burden of venous thromboembolism (VTE) is a challenging problem in the medical management of cancer patients. [...]
Highlights
The burden of venous thromboembolism (VTE) is a challenging problem in the medical management of cancer patients
The treatment of cancer patients for VTE has been associated with a high risk of recurrent thrombosis and of bleeding complications 7
Cancer patients who have VTE are at increased risk of mortality 10, but there are intriguing suggestions concerning the benefit of low molecular weight heparin for improved cancer survival 11
Summary
The burden of venous thromboembolism (VTE) is a challenging problem in the medical management of cancer patients. The well-known association between cancer and VTE 1 can be rigorously studied with modern molecular techniques 2. Large population-based epidemiologic studies have shed light on the relative frequency of VTE and cancer types 3,4, and clinical trials of cancer therapy have defined additional risk factors that compound the thrombotic risk 4–6
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
